# Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes

> **NCT03227484** · PHASE2 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 42 (actual)

## Conditions studied

- PreDiabetes
- Body Weight

## Interventions

- **DRUG:** Empagliflozin 25mg
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03227484
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-09
- **Primary completion:** 2019-10-25
- **Final completion:** 2019-11-18
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03227484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03227484, "Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03227484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*